Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte™ versus Valchlor® for the treatment of cutaneous T-cell lymphoma (CTCL) in the journal Oncology and Therapy. The study highlights favorable efficacy and safety outcomes for HyBryte, a novel photodynamic therapy utilizing visible light.
After 12 weeks of treatment, 60% of patients treated with HyBryte achieved treatment success compared to 20% for Valchlor. HyBryte also demonstrated a greater average improvement in disease severity and no treatment-related adverse events were reported. In contrast, Valchlor patients experienced multiple adverse reactions, supporting HyBryte’s potential as a well-tolerated therapy for early-stage CTCL.
The full press release detailing these findings is available at https://ibn.fm/Eq1BX. The results underscore the significant clinical advantage of HyBryte over the current standard of care, Valchlor, in terms of both efficacy and safety profile.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s Specialized BioTherapeutics business segment is advancing HyBryte™ (synthetic hypericin sodium) as a photodynamic therapy for CTCL, with successful completion of the second Phase 3 study. Regulatory approvals will be sought to support potential commercialization worldwide. Development programs also include expansion of synthetic hypericin (SGX302) into psoriasis, and other first-in-class therapies for inflammatory diseases.
According to the company, these positive results represent a significant milestone for Soligenix and for patients suffering from CTCL, a rare form of lymphoma that affects the skin. The data suggest that HyBryte could offer a more effective and safer treatment option, potentially improving quality of life for patients with early-stage disease.
The latest news and updates relating to Soligenix are available in the company’s newsroom at https://ibn.fm/SNGX. Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. For a detailed discussion of these risks, refer to the company's filings with the SEC.
